This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
-based OSF HealthCare's Childrens Hospital of Illinois became the first in the world to implant an extravascular implantable, cardioverter-defibrillator in a pediatric patient who had suffered sudden cardiacarrest.
Topics addressed by systematic reviews this year include resuscitation of cardiacarrest from drowning, extracorporeal cardiopulmonary resuscitation for adults and children, calcium during cardiacarrest, double sequential defibrillation, neuroprognostication after cardiacarrest for adults and children, maintaining normal temperature after preterm (..)
Praluent (alirocumab) (Approved: 03/11/2024) Extended to pediatric patients aged 8+ with heterozygous familial hypercholesterolemia (HeFH). These expanded approvals broaden treatment options across various patient populations, particularly in lipid management and cardiovascular risk reduction.
Pediatric and elderly patients were more predisposed to developing an arrhythmic event in the setting of fever [7]. Recently the rate of true arrhythmic events related to fevers in the classic Brugada Type 1 syndrome was explored by Michowitz et al.
The primary composite outcome included sustained ventricular arrhythmia, appropriate implantable cardioverter defibrillator (ICD) therapy, aborted cardiacarrest, or sudden cardiac death.RESULTS:A total of 100 primary prevention children were included (7.15.6 males), with a mean follow-up of 8.65.5
Further history later: This patient personally has no further high risk features (syncope / presyncope), but her mother had sudden cardiacarrest in sleep. Implantable Cardioverter-Defibrillator ), with long-term potential for device-related complications from the ICD, including inappropriate shocks?
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content